Research Output per year
Sandra Ortega Ugalde, MSc. studied Pharmacy at the University of the Basque Country (Spain) and worked thereafter as a pharmacist in Ireland for two years. In 2013 she started the Master in Drug Discovery and Safety at the VU University, Amsterdam, where she graduated with specialization in Molecular Toxicology. In July 2015, Sandra was awarded with one of the personal NWO AIMMS STAR (scientific top training in antimicrobial research) grants in the field of antimicrobials. With this grant Sandra started in September 2015 with a PhD research in the Molecular Toxicology and Molecular Microbiology research groups at the VU University. Her research aims at novel strategies to target Mycobacterium tuberculosis drug resistance by identifying and inhibiting constitutive and stress-induced mycobacterial cytochromes P450s (P450s) that are essential for the survival of the pathogen, avoiding off-target interaction with human P450s.
No ancillary activities
Last update Ancillary Activities: Amsterdam (2018-01-23)
Engineering a self-sufficient Mycobacterium tuberculosis CYP130 by gene fusion with the reductase-domain of CYP102A1 from Bacillus megateriumOrtega Ugalde, S., Luirink, R. A., Geerke, D. P., Vermeulen, N. P. E., Bitter, W. & Commandeur, J. N. M. 7 Dec 2017 In : Journal of Inorganic Biochemistry. p. 48 53 p., 180
Research output: Scientific - peer-review › Article